The mission of Case Comprehensive Cancer Center (Case CCC), now in its 25th year of NCI designation, is to promote a coordinated, translational research-oriented culture of scientific discovery applied to human cancers, with dissemination to patients and populations to improve cancer prevention, detection, treatment, cure, and survivorship. The Center provides leadership and oversight of collaboration for basic cancer research oriented toward identification of novel therapeutic targets; prevention, control and population research; therapeutic and non-therapeutic clinical research across the disease spectrum; and community outreach. The Center coordinates all aspects of cancer research in Cleveland and Northern Ohio, including activities of the affiliate institutions of Case Western Reserve University School of Medicine: Cleveland Clinic and University Hospitals. The Center provides opportunities to participate in clinical trials to almost 10,000 cancer patients who are newly diagnosed annually in the region. The opening in 2011 of the new freestanding cancer hospital, UH Seidman Cancer Center, and the funding of the Gl SPORE represent major achievements in this past grant cycle. The Case CCC is organized around 8 Scientific Programs, 15 shared resources, and a clinical and behavioral cancer research infrastructure that prioritizes innovative translational research and investigator-initiated clinical trials that ut across the Scientific Programs. The Case CCC includes 232 full members (335 total members) from 5 schools and 30 academic departments who actively participate in Cancer Center activities including Program and Core meetings and retreats, leadership committees, and scientific focus groups, each promoting a transdisciplinary approach that facilitates discovery and clinical application. The Cancer focus of the Center is exceptional, with over $116M in total funding and over $45M in total NCI funding. Institutional commitment is also exceptional with over $115M dedicated to cancer research in the next cycle and over $350M in construction anticipated. The Case CCC and its affiliate institutions have established an outstanding infrastructure that enables its members to improve the prevention, diagnosis, and treatment of cancer through discovery, implementation and dissemination, while providing state-of-the-art care and treatment to cancer patients and their families. The Case CCC is a significant partner with the NCI in its effort to change the practice of cancer care through discovery and clinical research of the highest quality.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-27
Application #
9295965
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2018-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
27
Fiscal Year
2017
Total Cost
$4,405,964
Indirect Cost
$1,626,176
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Patel, Rutulkumar; Qing, Yulan; Kennedy, Lucy et al. (2018) MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation. Stem Cells Transl Med 7:513-520
Desai, Amar; Zhang, Yongyou; Park, Youngsoo et al. (2018) A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica 103:1054-1064
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414

Showing the most recent 10 out of 1227 publications